Peptides: Short Chains of Amino Acids with Broad Biological Activity

Peptides are short polymers of amino acids linked together by covalent amide bonds known as peptide bonds. They occupy a middle ground in the hierarchy of biological macromolecules, being larger than individual amino acids but smaller than full proteins. By common convention, molecules containing up to roughly 50 amino acid residues are classified as peptides, while longer chains are considered proteins, although the boundary is not strictly defined.

Peptides perform a wide range of biological functions. They act as hormones, neurotransmitters, growth factors, immune regulators, and antimicrobial defense molecules. Many signaling molecules in the human body – such as oxytocin, glucagon, and the endogenous opioids – are peptides, and their small size allows them to bind cell-surface receptors with high specificity while penetrating tissues more readily than larger proteins.

The defining feature of a peptide is the peptide bond, a planar amide linkage formed when the carboxyl group (–COOH) of one amino acid reacts with the amino group (–NH2) of another, releasing a water molecule in a condensation reaction. The resulting C–N bond has partial double-bond character due to resonance, which restricts rotation and imposes geometric constraints on the peptide backbone. This rigidity is central to how peptides fold and adopt specific three-dimensional shapes.

Every peptide has a directional backbone running from a free amino group at one end (the N-terminus) to a free carboxyl group at the other (the C-terminus). Peptide sequences are always written from N-terminus to C-terminus using standard three- or one-letter amino acid abbreviations. The specific order of amino acid residues – the peptide's primary structure – is dictated by the genetic code when the peptide is produced biologically, although synthetic peptides can incorporate non-natural residues as well.

Peptides are commonly grouped by how they are produced: ribosomally in living cells, non-ribosomally by specialized enzyme complexes, or through chemical synthesis in the laboratory. By length, they are also described as dipeptides, tripeptides, oligopeptides (roughly under 20 residues), or polypeptides (longer chains approaching protein size), with shorter peptides tending to be more flexible and less likely to adopt the stable folded structures typical of proteins.

Most peptides in living organisms are produced through ribosomal protein synthesis. During translation, the ribosome reads a messenger RNA template and joins amino acids in the order specified by each codon. Many bioactive peptides, including insulin and most peptide hormones, are initially synthesized as larger precursor proteins that are enzymatically cleaved into their active short forms.

A distinct class of peptides is produced by bacteria and fungi through non-ribosomal peptide synthetases, large multi-enzyme complexes that assemble peptides without a ribosome or mRNA template. Non-ribosomal peptides often incorporate unusual features such as D-amino acids, cyclic structures, and modified side chains, which give them remarkable stability and potent biological activity. Clinically important antibiotics such as vancomycin and penicillin precursors originate from this biosynthetic route.

Chemists produce peptides in the laboratory primarily through solid-phase peptide synthesis, a method in which amino acids are added one at a time to a growing chain anchored to a solid resin support. Each step involves protection and deprotection of reactive groups to prevent unwanted side reactions. This approach enables the production of peptides with precisely defined sequences, including those containing non-natural amino acids, D-isomers, or cyclic architectures that cannot be made biologically.

Peptides serve diverse biological roles that broadly fall into several functional categories, each with distinct mechanisms and medical significance.

Peptide hormones regulate metabolism, growth, reproduction, and homeostasis by binding to cell-surface receptors and triggering intracellular signaling cascades. The nine-residue hormone oxytocin, which mediates social bonding and uterine contraction, was the first biologically active peptide to be chemically synthesized, in 1953. Glucagon counterbalances insulin in glucose regulation, and growth hormone-releasing peptides stimulate development. Insulin itself, at 51 residues across two disulfide-linked chains, sits at the boundary between peptides and small proteins but is often discussed alongside peptide hormones because it was the first therapeutic molecule of this general class, introduced clinically in 1922.

Neuropeptides are signaling peptides released by neurons that modulate mood, pain perception, appetite, and stress responses. Endorphins and enkephalins act as natural pain-relieving molecules by binding to opioid receptors, while substance P transmits pain signals and inflammatory responses. These peptides often coexist with classical neurotransmitters and fine-tune the activity of neural circuits over longer timescales than fast-acting small-molecule transmitters.

Antimicrobial peptides (AMPs) form a broad family of short, often cationic peptides that are part of the innate immune system in virtually all multicellular organisms. They kill bacteria, fungi, and viruses through mechanisms such as disrupting microbial membranes, inhibiting intracellular targets, or modulating host immune responses. Defensins, cathelicidins, and magainins are among the most studied AMP families, and their ability to target multidrug-resistant pathogens has made them attractive candidates for new biopharmaceuticals.

Many peptides derived from food proteins exhibit biological activities beyond basic nutrition. Enzymatic digestion of milk, soy, fish, and plant proteins liberates peptides with antihypertensive, antioxidant, antimicrobial, and immunomodulatory effects. These bioactive peptides underpin the development of functional foods and nutraceuticals, and they also serve as leads for pharmaceutical discovery.

Peptides have become a major class of pharmaceutical agents, occupying a space between small-molecule drugs and large biologics such as monoclonal antibodies. Their high specificity for biological targets, combined with generally lower immunogenicity than protein therapeutics and better tissue penetration than full antibodies, makes them valuable across multiple therapeutic areas. Roughly 100 peptide drugs have reached the market worldwide, with many more under active clinical investigation.

Peptide therapeutics are particularly prominent in treating metabolic diseases. The GLP-1 receptor agonists liraglutide and semaglutide, analogues of the gut hormone glucagon-like peptide-1, are now widely used in the management of type 2 diabetes and obesity. Other clinically important peptide drugs include the HIV fusion inhibitor enfuvirtide, the pain-relieving peptide ziconotide derived from cone snail venom, and teduglutide for short bowel syndrome, which is produced using recombinant DNA technology in engineered bacteria.

A central challenge in peptide drug development is overcoming natural limitations such as rapid enzymatic degradation, short plasma half-life, and poor oral bioavailability. Native GLP-1, for example, has a half-life of less than two minutes in blood. Chemical modifications including amino acid substitution, cyclization, fatty acid conjugation, and the incorporation of D-amino acids can extend peptide half-lives from minutes to days and enable less frequent dosing.

Beyond direct therapeutic use, peptides are powerful tools in biotechnology. Short peptide sequences are widely used as epitope tags for protein purification and detection, while cell-penetrating peptides enable the delivery of otherwise impermeable cargoes – including nucleic acids and large proteins – into the cytoplasm of living cells. Alongside aptamers, peptide-based affinity reagents complement and, in some applications, rival antibodies because of their lower cost, greater stability, and easier chemical modification.

Peptides also play a central role in nanoscale science and engineering. Certain short sequences self-assemble into well-defined nanostructures such as fibers, tubes, and hydrogels, which find use in drug delivery, tissue engineering scaffolds, and regenerative medicine. The surfaces of nanoparticles can be functionalized with targeting peptides to direct therapeutics selectively to tumors or inflamed tissues, and peptide-coated biosensors provide highly selective platforms for detecting biomarkers at clinically relevant concentrations.

In vaccine development, synthetic peptides representing key epitopes of a pathogen can elicit targeted immune responses without requiring the whole organism or its full proteins. This approach enables precise control over which antigens are presented to the immune system, offering advantages for designing vaccines against rapidly mutating viruses and cancers. Peptide-based cancer vaccines that train the immune system to recognize tumor-specific mutations are an active area of clinical investigation, alongside complementary platforms such as mRNA vaccines.

Display technologies such as phage display and mRNA display allow researchers to screen libraries of billions of peptide sequences against a target molecule, identifying those with the tightest and most specific binding. Machine learning models trained on large datasets of peptide sequences and their activities now complement these screens by predicting binding affinity, antimicrobial potency, and stability from sequence alone. Bioinformatics approaches also guide the engineering of peptidomimetics – molecules that mimic peptide structure and function while incorporating non-peptide elements to resist enzymatic degradation.

The therapeutic potential of peptides has made them one of the fastest-growing categories in the biohacking and longevity community, where compounds such as BPC-157, TB-500, CJC-1295, ipamorelin, and GHK-Cu are widely promoted for tissue repair, growth hormone release, and anti-aging effects. The underlying biology is real – peptides can be engineered to trigger specific physiological responses – but the evidence base for most of these compounds remains thin. The majority have never been tested in large-scale human clinical trials, and the consumer market has largely outpaced the science. Regulatory status is equally unsettled: in late 2023 the FDA placed several popular biohacking peptides on its Category 2 list, restricting compounding access, though reclassification to Category 1 has been announced but not yet formally published as of early 2026. A detailed evaluation of individual peptide compounds, their evidence levels, and the regulatory landscape can be found in our guide to nanotechnology in biohacking.

Despite their growing clinical importance, peptides face persistent challenges as drugs. Their susceptibility to proteases in the digestive tract has long restricted most peptide therapies to injectable formulations, limiting patient convenience. Recent advances in chemical modification, enteric coatings, permeation enhancers, and nanoparticle-based delivery systems are gradually enabling oral peptide drugs, with orally available semaglutide now approved as a proof of concept for this approach.

Improving peptide stability, selectivity, and manufacturing scalability remains an active area of research. Cyclization strategies that lock peptides into defined three-dimensional shapes yield molecules with enhanced proteolytic resistance and target specificity, while continuous-flow solid-phase synthesis is reducing the cost and environmental footprint of peptide production. For antimicrobial peptides, the challenge of avoiding toxicity to host cells while maintaining activity against drug-resistant pathogens is driving the design of optimized synthetic variants.

The intersection of peptides with synthetic biology, proteomics, and personalized medicine is opening new avenues. Patient-specific neoantigen peptide vaccines, engineered microbes that secrete therapeutic peptides, and peptide-nanoparticle conjugates tailored to individual disease profiles are all under active investigation. As synthesis, design, and delivery capabilities continue to advance, peptides are positioned to play a growing role in medicine and biotechnology.

Signal Transduction and Targeted Therapy, Therapeutic peptides: current applications and future directions

Nature Reviews Microbiology, Antimicrobial peptides: structure, functions and translational applications

Chemical Reviews, Advances in Peptidomimetics for Next-Generation Therapeutics: Strategies, Modifications, and Applications